Sandeep Nayak

Physician-Scientist

Data updated

Papers

30 publications

Trials

2 clinical trials

Research Footprint

Sandeep Nayak appears in 30 tracked papers (2020–2026) and 2 clinical trials, most studied alongside Psilocybin, DMT and LSD, across Depressive Disorders, Anxiety Disorders and Substance Use Disorders (SUD).

Most-cited paper: Psychedelics, placebo effects, and set and setting: insights from common factors theory of psychotherapy (145 citations).

Frequent co-authors: David Yaden, Albert Garcia-Romeu and Roland Griffiths.

Publication Landscape

How the 30 papers Blossom tracks for Sandeep Nayak line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.

How has Sandeep Nayak's publishing grown?

Sourced

Tracked papers by publication year. Click a year for the running total.

6papers published in 2023

+50% vs 2022

14 published by 2023

Browse papers

Don't read as total output: only the 30 of 30 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.

What does Sandeep Nayak publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.

Where does Sandeep Nayak publish?

Sourced

Tracked papers per journal. Orange marks the most-used journal.

Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.

Background & Research

Sandeep Nayak, MD, is a physician‑scientist affiliated with Johns Hopkins whose research focuses on the clinical, cognitive and safety consequences of classic psychedelics in both naturalistic and research settings. He has led and co‑authored prospective longitudinal work examining how psilocybin experiences alter mind perception and related belief systems, and has contributed to multiple analyses that probe drug–drug interactions and adverse events (for example, attenuation of psilocybin effects associated with SSRI/SNRI exposure and seizure risk signals when classic psychedelics are co‑administered with lithium). His publications also include comparative investigations of psychedelic and non‑ordinary experiences (such as near‑death experiences) and analyses of single transformative psychedelic experiences and their effects on attribution of consciousness to living and non‑living entities.

Beyond substantive clinical studies, Nayak has emphasised methodological rigour in psychedelic science — advocating for improved adverse‑event surveillance, reducing reporting bias and applying Bayesian approaches to trial design and analysis. He collaborates with neuroimaging groups and multidisciplinary teams to link phenomenology, safety, and neural measures, aiming to translate observational and experimental findings into safer, better‑characterised interventions for psychiatric care.

Key Impact

Known for empirical and methodological work on psychedelic-induced belief change, naturalistic psilocybin outcomes, and safety signals from drug co‑administration that inform clinical practice and trial design.

30

Research Papers

View publications →

2

Clinical Trials

Explore trials →

Collaboration Network

35 collaborators· click a node to visit their profile

Full network →

Collaboration Network

See Sandeep Nayak's full collaboration network, shared papers, and research connections.

Affiliations

Institutions, companies, and organisations Sandeep Nayak is associated with.